Home › Allergan may turn sights to Amgen or AbbVie with Teva cash
 

Keywords :   


Allergan may turn sights to Amgen or AbbVie with Teva cash

2015-07-28 18:30:04| Biotech - Topix.net

Allergan Plc says it's “reloaded and ready to move” on further acquisitions after agreeing to sell its generic-drug business for $40.5 billion. The deal with Teva Pharmaceutical Industries Ltd. “gives us a tremendous amount of flexibility to think about transformational M&A as well as continue our pattern of tuck-in acquisitions,” Allergan Chief Executive Officer Brent Saunders said on a conference call today.

Tags: with turn cash sights

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.11Atlantic Tropical Weather Outlook
02.11Eastern North Pacific Tropical Weather Outlook
02.11Tropical Depression Thirteen-E Graphics
02.11Summary for Tropical Depression Thirteen-E (EP3/EP132024)
02.11Fragrancing Spaces with Atmos, A Smart Home Diffuser
02.11Eastern North Pacific Tropical Weather Outlook
02.11Atlantic Tropical Weather Outlook
01.11Tropical Depression Thirteen-E Forecast Discussion Number 1
More »